Abstract
The immune system plays an important role in the control and elimination of malignant cells.In recent years, immunotherapy for treating tumors has received much attention due to its remarkable effects.There are currently two approaches to lead the field: programmed cell death protein-1/programmed death ligand-1 (PD-1/PD-L1) monoclonal antibody and killer cell immunoglobulin-like receptor (KIR)monoclonal antibody.It has been reported that PD-1/PD-L1 monoclonal antibody can reverse the inhibitory effect of activating T cells to kill tumor cells and thus exert a significant clinical response in patients with hematological tumors. KIR monoclonal antibody enhance the anti-tumor response of natural killer (NK) cells.It is a promising therapeutic strategy to mobilize both T cell and NK cell immune effector cells by PD-1/PD-L1 monoclonal antibody and KIR monoclonal antibody to produce synergistic anti-tumor response.This article intends to review the application of two antibodies in hemotological neoplasms. Key words: Immunotherapy; Suppressor factors, immunologic; Cell death; Receptors, natural killer cell; Hematologic neoplasms
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
